"Our results are the first observation of protection of vision in an RP model by MANF, and add a seminal functional visual acuity readout to the initial morphological protection findings reported from the University of Miami's Bascom Palmer Eye Institute," said Dr. David A. Lowe, President & CEO of NeuroAssets and member of the Amarantus Board of Directors. "These data further support our focus on ophthalmic orphan indications, as exemplified by our recent application to the FDA for orphan designation in RP."